Blaser Robert E, Kliger Alan S
Renal Physicians Association, Rockville, MD, USA.
Adv Chronic Kidney Dis. 2008 Jan;15(1):10-4. doi: 10.1053/j.ackd.2007.10.001.
In recent years, federal legislators and policymakers have increased their oversight of the Medicare program. This increased scrutiny accompanies federal budgetary constraint, the tenuous solvency of the Medicare program, changing congressional leadership, and safety concerns in health care. Two high-profile areas of focus have been the quality of care provided by physicians participating in the Medicare program and policies governing erythropoiesis-stimulating agents in the treatment of anemia. The nephrology community has sought to preserve its ability to provide appropriate, high-quality care to patients with chronic kidney disease (CKD). These efforts include establishing and monitoring quality measures and advocating for the best care and patient choice for those with CKD.
近年来，联邦立法者和政策制定者加强了对医疗保险计划的监督。这种加强审查的情况伴随着联邦预算限制、医疗保险计划脆弱的偿付能力、国会领导层的变化以及医疗保健中的安全问题。两个备受关注的领域是参与医疗保险计划的医生所提供的医疗质量以及治疗贫血的促红细胞生成素类药物的管理政策。肾脏病学界一直致力于维护其为慢性肾脏病（CKD）患者提供适当、高质量医疗服务的能力。这些努力包括制定和监测质量指标，以及为CKD患者争取最佳医疗服务和患者选择权。
